Phase 2 Prostate Cancer Trial, Recruiting NCT06675357 Sponsor: University of Wisconsin, Madison Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06675357
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You are able and willing to give your formal agreement to take part in the study
  • You have been diagnosed with prostate cancer
  • You are scheduled for, or have recently had (within the last 4 weeks), a standard PSMA PET scan as part of your normal care
  • Optionally, you are scheduled for a biopsy of a known or suspected cancer spread that is not in the bones or lymph nodes
  • You are willing and able to have a combined PET/MRI scan as part of this research study

Who may not be able to join:

  • You are unable or unwilling to give your formal agreement to take part
  • You have a medical reason why you cannot have a PET/MRI scan (for example, certain metal implants or other contraindications — confirm with trial site)
  • Having the PET/MRI scan would cause an unwanted delay to your cancer treatment
  • You need to be sedated with an intravenous (IV) drip to get through the scan — however, if you only need a mild, oral (taken by mouth) anti-anxiety medication, you may still be able to join provided all three of the following apply:
    • The medication has already been prescribed to you by your own doctor
    • You give your formal agreement to take part before taking the medication
    • You bring someone with you to drive you home on the day of the research visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ali Pirasteh, MD, University of Wisconsin, Madison

Phone: 608-282-8349

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
27 February 2026
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Performance of FAPI for lesion detection; Lesion FAPI uptake on PET; Total FAPI-positive tumor volume change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov